Article
Oncology
Sara S. Rinne, Charles Dahlsson Leitao, Ayman Abouzayed, Anzhelika Vorobyeva, Vladimir Tolmachev, Stefan Stahl, John Lofblom, Anna Orlova
Summary: The study suggests that affibody-based tracers are more suitable for PET imaging of HER3 expression, providing better imaging contrast and faster clearance from blood and normal organs.
Article
Multidisciplinary Sciences
Nadine Aschmoneit, Sophia Steinlein, Lennart Kuehl, Oliver Seifert, Roland E. Kontermann
Summary: This study developed bispecific antibodies for T-cell retargeting to HER3-expressing tumor cells, with scDb-scFv showing increased binding and more potent T-cell mediated cancer cell killing compared to scDb.
SCIENTIFIC REPORTS
(2021)
Review
Oncology
J. Uliano, C. Corvaja, G. Curigliano, P. Tarantino
Summary: Human epidermal growth factor receptor 3 (HER3) is a member of the HER family with weak oncogenic power, but can enhance oncogenesis, metastasis, and drug resistance through heterodimerization with HER2 and/or EGFR. Therapeutic targeting of HER3 through monoclonal antibodies or bispecific antibodies has shown unsatisfactory results, while antibody-drug conjugates have demonstrated promising activity in cancer treatment.
Article
Oncology
Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu
Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.
Article
Oncology
Hui Lyu, Fei Shen, Sanbao Ruan, Congcong Tan, Jundong Zhou, Ann D. Thor, Bolin Liu
Summary: Increased expression of HER3 is associated with poor prognosis in TNBC. Inhibition of HER3 expression inhibits TNBC cell proliferation and tumor growth. The anti-HER3 monoclonal antibody (mAb) 4A7 enhances the efficacy of gefitinib or paclitaxel in TNBC.
CANCER CELL INTERNATIONAL
(2023)
Review
Cell Biology
Avisek Majumder
Summary: HER3 is a receptor tyrosine kinase that lacks an active kinase domain and plays a role in tumorigenesis, tumor growth, and drug resistance in various cancer types. Targeting HER3 has been challenging due to its unique structure, but different approaches have been used, with limited clinical efficiency. Recent studies have questioned the applicability of HER3 antibody development for treatment, but HER3-directed antibody-drug conjugates show potential. Further research is needed to better understand HER3 signaling and develop more effective drugs.
Review
Chemistry, Medicinal
Sumika Toyama, Mitsutoshi Tominaga, Kenji Takamori
Summary: Itch is an unpleasant sensation that induces the desire to scratch and is a major symptom of many skin and systemic diseases. Histamine, a major itch mediator, may not be the only factor involved in chronic itch. Other treatment options for itch, such as antidepressants, antineuralgics, phototherapy, and acupuncture therapy, may be considered in addition to antihistamines, biologics, opioids, and JAK inhibitors.
Article
Oncology
Rami Abou Zeinab, H. Helena Wu, Yasser Abuetabh, Sarah Leng, Consolato Sergi, David D. Eisenstat, Roger P. Leng
Summary: Pirh2, a member of the RING-H2 family, has been identified as a key regulator of AIP4, inhibiting p73 function by downregulating AIP4 expression and ubiquitinating it. Despite AIP4's role in promoting p73 ubiquitination and degradation, Pirh2's interaction can disrupt the AIP4-p73 negative regulatory pathway and maintain p73 cell cycle arrest function.
Article
Oncology
Igor Odintsov, Marissa S. Mattar, Allan J. W. Lui, Michael Offin, Christopher Kurzatkowski, Lukas Delasos, Inna Khodos, Marina Asher, Robert M. Daly, Natasha Rekhtman, Elisa de Stanchina, Gopinath Ganji, Marc Ladanyi, Romel Somwar
Summary: This study established patient-derived xenograft (PDX) and cell line models of NRG1-rearranged lung adenocarcinoma, identifying the MTOR pathway as a potential vulnerability in this cancer subset. The results suggest that targeting the MTOR pathway could be a promising therapeutic strategy for patients with NRG1 fusion-positive lung adenocarcinoma.
JOURNAL OF THORACIC ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Dennis Y. Gout, Lotte S. Groen, Marjolein van Egmond
Summary: Monoclonal antibody (mAb) therapy has been successful in treating lymphomas and leukemias, but its efficacy is reduced in solid tumors due to an immune-suppressive tumor micro-environment. Antibody-cytokine fusion proteins, known as immunocytokines, provide a solution by acting as a local delivery platform and increasing the half-life of cytokines. These fusion proteins can activate cytotoxic immune cells and eliminate tumor cells. Current research focuses on exploring different antibody formats and cytokine payloads for the development of immunocytokines.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Cell Biology
Marcia R. Campbell, Ana Ruiz-Saenz, Yuntian Zhang, Elliott Peterson, Veronica Steri, Julie Oeffinger, Maryjo Sampang, Natalia Jura, Mark M. Moasser
Summary: This article presents an extensive structure-function analysis of HER2 and HER3 signaling in cancer treatment. It reveals that the extracellular domains (ECDs) of these receptors are not essential for tumorigenic signaling and their conformational changes do not affect the dimerization interface. Additionally, disruptive receptor engineering fails to disturb tumorigenic signaling. The overexpression of HER2 uncouples intracellular signaling from extracellular constraints.
Review
Oncology
Mary Kate Kilroy, SoYoung Park, Wasim Feroz, Hima Patel, Rosalin Mishra, Samar Alanazi, Joan T. Garrett
Summary: HER3, a member of the HER family, has been found to play a role in tumor growth and progression. Mutations in HER3 occur in various cancers and may lead to resistance to targeted therapies. Several HER3 targeting drugs are currently under development, potentially improving outcomes for cancer patients with HER3 activation or mutations.
Review
Oncology
Lucia Gandullo-Sanchez, Alberto Ocana, Atanasio Pandiella
Summary: HER3 protein is closely associated with the development of various tumors, and targeting HER3 has therapeutic relevance in promoting cell proliferation. Different types of agents targeting HER3 have been developed, including antibodies, aptamers, and vaccines. This article reviews the preclinical and clinical development of drugs targeting HER3.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Zhiyong Wang, Yusuke Goto, Michael M. Allevato, Victoria H. Wu, Robert Saddawi-Konefka, Mara Gilardi, Diego Alvarado, Bryan S. Yung, Aoife O'Farrell, Alfredo A. Molinolo, Umamaheswar Duvvuri, Jennifer R. Grandis, Joseph A. Califano, Ezra E. W. Cohen, J. Silvio Gutkind
Summary: The study suggests that HER3 inhibition can enhance the response to PD-1 blockade in HNSCC patients and may provide a multimodal precision immunotherapeutic approach for treating PIK3CA wild-type HNSCC.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Pranay Dey, Nikhil Gadewal, Abhijit De
Summary: Among the EGFR family, HER3 acts as a pseudo-kinase and primarily interacts with HER2 in the presence of heregulin-1 beta. The hotspot mutations G284R and D297Y, as well as the double mutant HER2-S310F/HER3-G284R, were identified in breast cancer patients. These mutations cause conformational changes in the flanking regions of HER2, resulting in an unstable heterodimer and abrogating downstream signalling. The HER3-D297Y mutation forms stable interactions with EGFR-WT in the presence of EGF or heregulin-1 beta, making cancer cells susceptible to EGFR-targeted drugs.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Oncology
Laura Bourillon, Sylvain Demontoy, Alexis Lenglet, Alexandre Zampieri, Julien Fraisse, Marta Jarlier, Florence Boissiere-Michot, Helene Perrochia, Gauthier Rathat, Veronique Garambois, Nathalie Bonnefoy, Henri-Alexandre Michaud, Thierry Chardes, Diego Tosi, Andre Pelegrin, David Azria, Christel Larbouret, Celine Bourgier
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2020)
Article
Medicine, Research & Experimental
Christel Larbouret, Marie-Alix Poul, Thierry Chardes
M S-MEDECINE SCIENCES
(2020)
Article
Multidisciplinary Sciences
Maeva Chauvin, Veronique Garambois, Pierre-Emmanuel Colombo, Myriam Chentouf, Laurent Gros, Jean-Paul Brouillet, Bruno Robert, Marta Jarlier, Karen Dumas, Pierre Martineau, Isabelle Navarro-Teulon, David Pepin, Thierry Chardes, Andre Pelegrin
Summary: In ovarian carcinoma, AMH has a pro-survival autocrine role, while anti-AMH antibody can successfully repress tumor growth, providing a novel therapeutic strategy for ovarian cancer.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Maeva Chauvin, Veronique Garambois, Sylvie Choblet, Pierre-Emmanuel Colombo, Myriam Chentouf, Laurent Gros, David-Paul De Brauwere, Martine Duonor-Cerutti, Karen Dumas, Bruno Robert, Marta Jarlier, Pierre Martineau, Isabelle Navarro-Teulon, David Pepin, Thierry Chardes, Andre Pelegrin
Summary: The study identified the main AMH type I receptors involved in ovarian cancer and designed tetravalent IgG1-like bispecific antibodies against AMHRII and ALK2, as well as against AMHRII and ALK3. In vivo experiments showed significant reduction in tumor growth with BsAb treatment, indicating a potential therapeutic approach to modulate AMH signaling.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2021)
Review
Oncology
Christel Larbouret, Laurent Gros, Andre Pelegrin, Thierry Chardes
Summary: The approval of novel antibody combinations or oligoclonal antibody mixtures in oncology has opened new pathways for improving the efficacy of cancer treatment, but further research is needed to optimize their formulation and delivery.
Article
Plant Sciences
G. Odonne, L. Musset, C. Cropet, B. Philogene, M. Gaillet, M-A Tareau, M. Douine, C. Michaud, D. Davy, L. Epelboin, Y. Lazrek, P. Brousse, P. Travers, F. Djossou, E. Mosnier
Summary: Residents in French Guiana's SGO rely on traditional phytotherapies and pharmaceutical drugs to treat malaria. This medical pluralism should be understood as a form of pragmatism: people collect or cultivate plants for medicinal purposes, which is more congruent with their respective cultures and shows a desire for independence in the care process. A better consideration of these practices is necessary to improve public health response to malaria.
JOURNAL OF ETHNOPHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Angela M. Early, Flavia Camponovo, Stephane Pelleau, Gustavo C. Cerqueira, Yassamine Lazrek, Beatrice Volney, Manuela Carrasquilla, Benoit de Thoisy, Caroline O. Buckee, Lauren M. Childs, Lise Musset, Daniel E. Neafsey
Summary: This study investigates the impact of declining infection rates on the investment of Plasmodium falciparum in sexual and asexual growth. Using a mathematical model and analyzing parasite genomes collected over an 18-year period, the study confirms the model's predictions and highlights the wide-ranging selection pressures imposed by public health interventions on basic parasite life history traits.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Lindsay B. Alcaraz, Aude Mallavialle, Caroline Mollevi, Florence Boissiere-Michot, Hanane Mansouri, Joelle Simony-Lafontaine, Valerie Laurent-Matha, Thierry Chardes, William Jacot, Andrei Turtoi, Pascal Roger, Severine Guiu, Emmanuelle Liaudet-Coopman
Summary: The study reveals that SPARC expression in cancer-associated fibroblasts (CAF) is an independent prognostic marker of poor outcome in triple-negative breast cancer (TNBC). The fibroblast-secreted SPARC also has a tumor-promoting role by inhibiting TNBC cell adhesion and stimulating their motility and invasiveness.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Immunology
Emilia Rabia, Veronique Garambois, Christine Dhommee, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Nelly Pirot, Gilles Thibault, Eugene A. A. Zhukovsky, Pierre-Emmanuel Gerard, Andre Pelegrin, Jacques Colinge, Thierry Chardes
Summary: Using the BiXAb(TM) tetravalent platform, we generated bispecific antibodies against EGFR, HER2, or HER3 and compared them with single antibodies and antibody pair combinations. We selected 3Patri-1Cetu-Fc, 3Patri-1Matu-Fc, and 3Patri-2Trastu-Fc as lead candidates and tested their efficacy in mouse models of pancreatic cancer. This semi-rational/semi-empirical approach represents the first attempt to identify potent bispecific antibodies against ErbB family members in pancreatic cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Olivier Duron, Rachid Koual, Lise Musset, Marie Buysse, Yann Lambert, Benoit Jaulhac, Denis Blanchet, Kinan Drak Alsibai, Yassamine Lazrek, Loic Epelboin, Pierre Deshuillers, Celine Michaud, Maylis Douine
Summary: A case of unusual human anaplasmosis in the Amazon rainforest of French Guiana is reported. Molecular typing revealed that the pathogen is a novel Anaplasma species, distinct from all known species, and more genetically related to recently discovered Anaplasma spp. causing infections in rainforest wild fauna of Brazil.
EMERGING INFECTIOUS DISEASES
(2022)
Article
Infectious Diseases
Luana C. Mathieu, Prabhjot Singh, Wuelton Marcelo Monteiro, Magda Magris, Horace Cox, Yassamine Lazrek, Gisely C. Melo, Paola Marchesini, Jean S. F. Alexandre, Angel Manuel Alvarez, Magalie Demar, Maylis Douine, Maria-Paz Ade, Marcus V. G. Lacerda, Lise Musset
Summary: The study found that there are few pfk13 mutant foci in Amazon basin countries, but there is a high risk of mutation dispersion mainly from the Guiana Shield due to mining activities.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Health Care Sciences & Services
Maylis Douine, Yann Lambert, Muriel Suzanne Galindo, Louise Mutricy, Alice Sanna, Cassio Peterka, Paola Marchesini, Helene Hiwat, Mathieu Nacher, Antoine Adenis, Magalie Demar, Lise Musset, Yassamine Lazrek, Hedley Cairo, Jane Bordalo Miller, Stephen Vreden, Martha Suarez-Mutis
Summary: This quasi-experimental research project in French Guiana has demonstrated the effectiveness of distributing self-diagnosis and self-treatment kits to illegal gold miners, leading to an increase in the use of certified ACT after a positive malaria diagnosis and a significant decline in malaria incidence in the region.
LANCET REGIONAL HEALTH-AMERICAS
(2021)
Article
Medicine, Research & Experimental
Lindsay B. Alcaraz, Aude Mallavialle, Timothee David, Danielle Derocq, Frederic Delolme, Cindy Dieryckx, Caroline Mollevi, Florence Boissiere-Michot, Joelle Simony-Lafontaine, Stanislas Du Manoir, Pitter F. Huesgen, Christopher M. Overall, Sophie Tartare-Deckert, William Jacot, Thierry Chardes, Severine Guiu, Pascal Roger, Thomas Reinheckel, Catherine Moali, Emmanuelle Liaudet-Coopman
Summary: This study identified a novel crosstalk between proteases and matricellular proteins in the tumor microenvironment through limited SPARC proteolysis, revealing a novel targetable 9-kDa bioactive SPARC fragment for new TNBC treatments. The research paves the way for developing strategies to target bioactive fragments from matricellular proteins in TNBC.
Article
Medicine, Research & Experimental
Emilia Rabia, Veronique Garambois, Julie Hubert, Marine Bruciamacchie, Nelly Pirot, Helene Delpech, Morgane Broyon, Charles Theillet, Pierre-Emmanuel Colombo, Nadia Vie, Diego Tosi, Celine Gongora, Lakhdar Khellaf, Marta Jarlier, Nina Radosevic-Robin, Thierry Chardes, Andre Pelegrin, Christel Larbouret
Summary: Chemoresistance, particularly to gemcitabine, presents a significant challenge in pancreatic cancer, and the expression of EGFR, HER2, and HER3 is associated with tumor aggressiveness and therapeutic resistance. Antibody cocktails targeting these three receptors have shown promise in overcoming resistance in both gemcitabine-sensitive and -resistant pancreatic cancer models.
